Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Diabetes Drug CV Outcomes Trials May Be Needed For Market Success But Not Approval, US FDA Panel Says

Oct 29 2018

• By Sue Sutter

Diabetes

Related Content

US FDA Panel Will Reckon With Need For Diabetes Drug CV Risk Assessments

Oct 22 2018

Diabetes Drugs: Longer, Broader Phase II/III Trials Could Replace CV Outcomes Trials, US Panel Says

Oct 26 2018

Merck Blocked In Adding CV Claim For Januvia, May Fall Behind Victoza

Apr 07 2017

Related Companies

Boehringer Ingelheim GmbH

Eli Lilly and Company

Novo Nordisk A/S

GSK plc

Merck & Co., Inc.

AstraZeneca PLC

Sanofi

Additional Topics

United States Advisory Committees Drug Approval Standards Drug Safety Regulation BioPharmaceutical Metabolic Disorders

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window